LT3143011T - Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų - Google Patents

Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų

Info

Publication number
LT3143011T
LT3143011T LTEP15725253.7T LT15725253T LT3143011T LT 3143011 T LT3143011 T LT 3143011T LT 15725253 T LT15725253 T LT 15725253T LT 3143011 T LT3143011 T LT 3143011T
Authority
LT
Lithuania
Prior art keywords
heterocyclic compounds
deuterated
imagining agents
imagining
deuterated heterocyclic
Prior art date
Application number
LTEP15725253.7T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jan Marik
Joseph P. Lyssikatos
Simon Williams
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of LT3143011T publication Critical patent/LT3143011T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
LTEP15725253.7T 2014-05-13 2015-05-12 Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų LT3143011T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461992717P 2014-05-13 2014-05-13
PCT/EP2015/060447 WO2015173225A1 (en) 2014-05-13 2015-05-12 Deuterated heterocyclic compounds and their use as imaging agents

Publications (1)

Publication Number Publication Date
LT3143011T true LT3143011T (lt) 2021-05-10

Family

ID=53269446

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15725253.7T LT3143011T (lt) 2014-05-13 2015-05-12 Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų

Country Status (21)

Country Link
US (4) US10076581B2 (enExample)
EP (2) EP3143011B1 (enExample)
JP (2) JP6529986B2 (enExample)
KR (2) KR102618139B1 (enExample)
CN (2) CN106459059B (enExample)
AU (2) AU2015261008B2 (enExample)
CA (1) CA2948721C (enExample)
DK (1) DK3143011T3 (enExample)
ES (1) ES2867814T3 (enExample)
HR (1) HRP20210641T1 (enExample)
HU (1) HUE053939T2 (enExample)
IL (3) IL280791B2 (enExample)
LT (1) LT3143011T (enExample)
MX (2) MX376163B (enExample)
PL (1) PL3143011T3 (enExample)
PT (1) PT3143011T (enExample)
RS (1) RS61810B1 (enExample)
RU (1) RU2696492C2 (enExample)
SG (2) SG11201609281UA (enExample)
SI (1) SI3143011T1 (enExample)
WO (1) WO2015173225A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX376163B (es) 2014-05-13 2025-03-07 Hoffmann La Roche Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.
EP3487545A1 (en) 2016-07-22 2019-05-29 AC Immune S.A. Compounds for imaging tau protein aggregates
WO2018015549A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
MX2019005007A (es) * 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
WO2019169111A1 (en) 2018-03-02 2019-09-06 The Trustees Of The University Of Pennsylvania [1,2,4]triazolo[1,5-a]pyrimidine compounds and use in stabilizing microtubules
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
JP7337174B2 (ja) 2018-09-18 2023-09-01 ニカング セラピューティクス, インコーポレイテッド Srcホモロジー-2ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体
EP4218934B1 (en) 2018-10-05 2025-06-18 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 30 (usp30)
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
JP7119978B2 (ja) * 2018-12-20 2022-08-17 オムロン株式会社 制御装置およびプログラム
CA3138873C (en) * 2019-05-09 2024-01-09 Kyle Bradley Pascual CLAGG Synthesis of labeled imidazo[1,2-a]pyrimidines
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
CN113526526A (zh) * 2021-07-12 2021-10-22 苏州大学 氘代氨制备方法及以其作为氘源参与的氘代反应
WO2023028591A1 (en) 2021-08-27 2023-03-02 Genentech, Inc. Methods of treating tau pathologies
EP4536358A1 (en) 2022-06-13 2025-04-16 Genentech Inc. Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
WO2025155625A1 (en) * 2024-01-16 2025-07-24 Eli Lilly And Company Novel compounds for tau imaging
CN118957609B (zh) * 2024-07-23 2025-09-09 无锡绿能电合科技有限公司 一种氟代芳环的氘代方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD76515A (enExample) *
DE76515C (de) F. MORA in Mailand Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff
EP1340759A1 (en) 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
PL1999109T3 (pl) * 2006-03-30 2012-05-31 Univ Pennsylvania Pochodne styrylopirydyny i ich zastosowanie do wiązania i obrazowania blaszek amyloidowych
JP5647519B2 (ja) 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ[d][1,3]ジオキソールおよびその誘導体の合成
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
EP2599763A1 (en) 2008-02-14 2013-06-05 Siemens Molecular Imaging, Inc. Novel imaging agents for detecting neurological dysfunction
US20100144657A1 (en) 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CN102438660A (zh) 2009-03-23 2012-05-02 美国西门子医疗解决公司 用于检测神经障碍的显像剂
EP2450332A1 (en) * 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
KR20140003438A (ko) * 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
JP5976206B2 (ja) * 2012-05-22 2016-08-23 イーライ リリー アンド カンパニー 神経機能障害を検出するための造影剤
AU2014333996B2 (en) * 2013-10-08 2018-03-15 F. Hoffmann-La Roche Ag Diazacarbazole derivatives as tau-pet-ligands
MX376163B (es) 2014-05-13 2025-03-07 Hoffmann La Roche Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.

Also Published As

Publication number Publication date
BR112016026443A8 (pt) 2021-07-06
CA2948721A1 (en) 2015-11-19
CN110483522A (zh) 2019-11-22
IL248692A0 (en) 2017-01-31
MX2016014615A (es) 2017-03-06
IL280791A (en) 2021-04-29
IL280791B2 (en) 2024-03-01
JP2019147825A (ja) 2019-09-05
PT3143011T (pt) 2021-04-26
US20200297875A1 (en) 2020-09-24
JP2017515856A (ja) 2017-06-15
IL271631A (en) 2020-02-27
KR20170002639A (ko) 2017-01-06
HUE053939T2 (hu) 2021-08-30
MX376163B (es) 2025-03-07
CN106459059B (zh) 2019-09-24
ES2867814T3 (es) 2021-10-20
RU2696492C2 (ru) 2019-08-02
SG10201805628TA (en) 2018-08-30
US20230218782A1 (en) 2023-07-13
NZ726208A (en) 2023-11-24
CN110483522B (zh) 2022-05-03
US10076581B2 (en) 2018-09-18
AU2019203369A1 (en) 2019-06-06
US20190201561A1 (en) 2019-07-04
RU2016147742A (ru) 2018-06-18
BR112016026443A2 (pt) 2017-08-15
MX2020010847A (es) 2021-07-16
PL3143011T3 (pl) 2021-07-19
AU2015261008A1 (en) 2016-11-17
MX384604B (es) 2025-03-14
HRP20210641T1 (hr) 2021-05-28
IL280791B1 (en) 2023-11-01
US12214058B2 (en) 2025-02-04
JP6681498B2 (ja) 2020-04-15
EP3143011A1 (en) 2017-03-22
IL248692B (en) 2020-01-30
RS61810B1 (sr) 2021-06-30
AU2019203369B2 (en) 2020-06-04
KR102530129B1 (ko) 2023-05-10
KR102618139B1 (ko) 2023-12-27
SG11201609281UA (en) 2016-12-29
US11504440B2 (en) 2022-11-22
CA2948721C (en) 2023-03-28
RU2016147742A3 (enExample) 2018-10-08
NZ764181A (en) 2023-11-24
JP6529986B2 (ja) 2019-06-12
WO2015173225A1 (en) 2015-11-19
KR20230035445A (ko) 2023-03-13
DK3143011T3 (da) 2021-05-03
EP3901145A1 (en) 2021-10-27
EP3143011B1 (en) 2021-03-03
US10675367B2 (en) 2020-06-09
AU2015261008B2 (en) 2019-02-14
CN106459059A (zh) 2017-02-22
SI3143011T1 (sl) 2021-08-31
US20160250358A1 (en) 2016-09-01
IL271631B (en) 2021-05-31

Similar Documents

Publication Publication Date Title
IL280791A (en) Deuterium compounds and their use
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
LT3221306T (lt) Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas
LT3102555T (lt) Junginių kompozicijos ir jų panaudojimas
GB201403093D0 (en) Therapeutic compounds and their use
IL246978A0 (en) Novel pharmaceutical formulations
LT2970303T (lt) Pakeistieji ksantinai ir jų panaudojimo metodai
HRP20190432T1 (hr) Spojevi pladienolid piridina i postupci uporabe
LT3129019T (lt) Artemizinino junginių ir gefirino agonistų medicininis panaudojimas
PL3194421T3 (pl) Związki cytotoksyczne i przeciwmitotyczne oraz sposoby ich wykorzystania
LT3197898T (lt) Nauji imidazopiridazino junginiai ir jų panaudojimas
HUE054245T2 (hu) Immunszupresszáns formuláció
IL251904B (en) Apilimod for use in the treatment of melanoma
LT3231793T (lt) Dihidropirimidin-2-ono junginiai ir jų medicininis panaudojimas
DK3193840T3 (da) Arimoclomol-formulering
PT3212237T (pt) Formulação de metotrexato
IL264445A (en) Compounds and compositions and uses thereof
CL2016002705A1 (es) Formulación agroquímica
DK3148513T3 (da) Ceritinib-formulering
EP3181125C0 (en) CAPSULE FORMULATION
FR3021528B1 (fr) Formulation cosmetique
DK3193856T3 (da) Formulering
ES1119005Y (es) Prenda reversible desmontable
LT3518927T (lt) 1-fenilpropanono junginiai ir jų panaudojimas
TH1701000764A (th) สูตรผสมฆ่าเชื้อและการใช้งานของสูตรผสมนั้น